- |||||||||| ATB1651 / AmtixBio
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: A Study of ATB1651 in Adults With Mild to Moderate Onychomycosis (clinicaltrials.gov) - Oct 11, 2023
P1, N=30, Completed,
Collectively, our results imply that ATB1651 gel is a safe candidate for clinical development as an antifungal drug with a wide therapeutic window. Recruiting --> Completed | N=60 --> 30 | Trial completion date: Feb 2024 --> Sep 2023 | Trial primary completion date: Sep 2023 --> Jun 2023
- |||||||||| ATB1651 / AmtixBio
Enrollment open, Trial completion date, Trial primary completion date: A Study of ATB1651 in Adults With Mild to Moderate Onychomycosis (clinicaltrials.gov) - Jul 29, 2022
P1, N=60, Recruiting,
Recruiting --> Completed | N=60 --> 30 | Trial completion date: Feb 2024 --> Sep 2023 | Trial primary completion date: Sep 2023 --> Jun 2023 Not yet recruiting --> Recruiting | Trial completion date: Apr 2023 --> Feb 2024 | Trial primary completion date: Apr 2023 --> Sep 2023
|
